# US 2026/0034111 A1 · NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0034111 A1
- Document ID: US20260034111A1
- Status: Published application
- Kind: A1
- Application number: 18/997,666
- Filed: 2023-07-25
- Published: 2026-02-05
- Earliest claimed: 2022-07-25
- Assignees: Cayman Chemical Company, Incorporated
- Applicants: Cayman Chemical Company Incorporated
- Inventors: Zahra Assar-Nossoni; Stephen Douglas Barrett; Fred Lawrence Ciske; Andrei Mikhailovich Kornilov; James Bernard Kramer; Kirk Lang Olson; Sreenu Jennepalli
- Web page: https://patentgrep.com/patent/US20260034111A1

## CPC

- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4427: containing further heterocyclic ring systems
- A61K 31/4436: containing a heterocyclic ring having sulfur as a ring hetero atom
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 35/00: Antineoplastic agents
- C07D 209/42: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 307/85: attached in position 2
- C07D 333/70: attached in position 2
- C07D 345/00: Heterocyclic compounds containing rings having selenium or tellurium atoms as the only ring hetero atoms
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/14: containing three or more hetero rings
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 421/04: directly linked by a ring-member-to-ring-member bond
- C07D 471/04: Ortho-condensed systems
- C07D 495/04: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions of the compounds, or salts thereof, that can inhibit secreted phospholipases A2 (sPLA2-X) enzymes, wherein the compound is a compound of Formula (I), wherein Ring B, R6, Z1, Z2, Z3, and Z4 are described herein. The invention also relates to the use of the compounds, salts, or compositions described herein in methods of inhibiting sPLA2-X enzymes in a sample. The invention also relates to the use of the compounds, salts, or compositions in methods of treating or lessening the severity of an sPLA2-X mediated disease in a subject.

## Claims

### Claim at position 1

1-121. (canceled)

### Claim 122

A compound of Formula IIIf-1, IIIf-2, IIIf-3, IIIf-4, IIIf-5, IIIf-6, or IIIf-7:
or a pharmaceutically acceptable salt thereof, wherein
X1-X3 are each independently N or CH;
R1 is H or R7;
R2f is selected from hydrogen CN, OH, NH2, halo, and C1-6 alkyl;
R5f is selected from hydrogen, CN, OH, NH2, halo, C1-6 alkyl, and OC1-6 alkyl;
R3f and R4f, together with the carbon atom to which they are attached, form a 3-6 membered cyclyl or a 3-6 membered heterocyclyl, wherein each cyclyl and heterocyclyl are optionally substituted with one or more R10 substituents.
each R7 is independently R10;
each R10 is selected from oxo, CN, OR11, N(R11)2, halo, C(O)H, C(O)R11, C(O)OR1, C(O)N(R1)2, (C1-6 alkyl)-C(O)R11, (C1-6 alkyl)-C(O)OR11, (C1-6 alkyl)-C(O)N(R11)2, N(R11)C(O)R11, N(R11)C(O)OR11, N(R11)C(O)NHR11, N(Ri)-(CH2)—C(O)R11, N(R11)—(CH2)—C(O)OR11, N(R11)—(CH2)—C(O)NHR11, N(R11)SO2C1-6 alkyl, OSO2C1-6 alkyl, SO2C1-6 alkyl, S(O)2N(R11)2, C1-6 alkyl, a phenyl, a 3-6 membered cyclyl, a 3-6 membered heterocyclyl, or a 5 or 6 membered heteroaryl, wherein each alkyl, phenyl, cyclyl, heterocyclyl, or heteroaryl are each independently and optionally substituted with one or more R11 substituents;
each R11 is independently selected from hydrogen, oxo, CN, OH, NH2, halo, OC1-6 alkyl, OC1-6 haloalkyl, C1-6 alkyl, and C1-6 haloalkyl;
each R12 is independently selected from OH, OC1-6 alkyl, O-phenyl, NH2, NH(C1-6 alkyl), and N(C1-6 alkyl)2, wherein each alkyl and phenyl are optionally and independently substituted with one to three R10 substituents; and
n is an integer selected from 0, 1, 2, and 3.

### Claim 123 (depends on 122)

The compound or pharmaceutically acceptable salt thereof according to claim 122, wherein R3f and R4f, together with the carbon atom to which they are attached, form a 3-6 membered cyclyl optionally substituted with one or more C1-6 alkyl substituents.

### Claim 124 (depends on 123)

The compound or pharmaceutically acceptable salt thereof according to claim 123, wherein R3f and R4f, together with the carbon atom to which they are attached, form a cyclopropyl or cyclobutyl moiety, which is optionally substituted with one or more C1-6 alkyl substituents.

### Claim 125 (depends on 122)

The compound or pharmaceutically acceptable salt thereof according to claim 122, wherein R1 is H.

### Claim 126 (depends on 122)

The compound or pharmaceutically acceptable salt thereof according to claim 122, wherein each R7 is independently selected from CN, OC1-6 alkyl, halo, and C1-6 alkyl.

### Claim 127 (depends on 126)

The compound or pharmaceutically acceptable salt thereof according to claim 126, wherein each R7 is independently selected from halo and C1-6 alkyl, and n is 0 or 1.

### Claim 128 (depends on 127)

The compound or pharmaceutically acceptable salt thereof according to claim 127, wherein n is 0.

### Claim 129 (depends on 122)

The compound or pharmaceutically acceptable salt thereof according to claim 122, wherein the moiety

### Claim 130 (depends on 122)

The compound or pharmaceutically acceptable salt thereof according to claim 122, wherein the compound is selected from:
Compound
Name
Structure
15
trans-(rac)-2-(3-(2-carbamoyl-6- (trifluoromethoxy)-1H-indol-1- yl)phenyl)cyclopropane-1-carboxylic acid
15b
trans-(−)-2-(3-(2-carbamoyl-6- (trifluoromethoxy)-1H-indol-1- yl)phenyl)cyclopropane-1-carboxylic acid
28
trans-(rac)-2-(6-(2-carbamoyl-6- (trifluoromethoxy)-1H-indol-1- yl)pyridin-2-yl)cyclopropane-1- carboxylic acid
28a
trans-(−)-2-(6-(2-carbamoyl-6- (trifluoromethoxy)-1H-indol-1- yl)pyridin-2-yl)cyclopropane-1- carboxylic acid
28b
trans-(+)-2-(6-(2-carbamoyl-6- (trifluoromethoxy)-1H-indol-1- yl)pyridin-2-yl)cyclopropane-1- carboxylic acid
28c
cis-(rac)-2-(6-(2-carbamoyl-6- (trifluoromethoxy)-1H-indol-1- yl)pyridin-2-yl)cyclopropane-1- carboxylic acid
28d
cis-(−)-2-(6-(2-carbamoyl-6- (trifluoromethoxy)-1H-indol-1- yl)pyridin-2-yl)cyclopropane-1- carboxylic acid
28e
cis-(+)-2-(6-(2-carbamoy1-6- (trifluoromethoxy)-1H-indol-1- yl)pyridin-2-yl)cyclopropane-1- carboxylic acid
38b
trans-2-(3-(2-carbamoyl-6- (trifluoromethoxy)-1H-indol-1- yl)phenyl)-2-methylcyclopropane-1- carboxylic acid
51
trans-2-(6-(2-carbamoyl-6-methoxy- 1H-pyrrolo[3,2-b]pyridin-1-yl)pyridin- 2-yl)cyclopropane-1-carboxylic acid
56
trans-2-(6-(2-carbamoyl-5- (trifluoromethoxy)benzo[b]thiophen-3- yl)pyridin-2-yl)cyclopropane-1- carboxylic acid
57
trans-2-(6-(2-carbamoyl-5- (trifluoromethoxy)benzo[b]selenophen- 3-yl)pyridin-2-yl)cyclopropane-1- carboxylic acid
58
trans-2-(6-(2-carbamoyl-6- (trifluoromethoxy)-1H- benzo[d]imidazol-1-yl)pyridin-2- yl)cyclopropane-1-carboxylic acid
65
trans-2-(6-(2-carbamoylthieno[2,3- c]pyridin-3-yl)pyridin-2- yl)cyclopropane-1-carboxylic acid
66
trans-2-(6-(2-carbamoyl-6-methoxy- 1H-pyrrolo[3,2-c]pyridin-1-yl)pyridin- 2-yl)cyclopropane-1-carboxylic acid

### Claim 131 (depends on 130)

The compound or pharmaceutically acceptable salt thereof according to claim 130, wherein the compound is selected from:
Compound
Name
Structure
28a
trans-(−)-2-(6-(2-carbamoyl-6- (trifluoromethoxy)-1H-indol-1- yl)pyridin-2-yl)cyclopropane-1- carboxylic acid
28b
trans-(+)-2-(6-(2-carbamoyl-6- (trifluoromethoxy)-1H-indol-1- yl)pyridin-2-yl)cyclopropane-1- carboxylic acid
28d
cis-(−)-2-(6-(2-carbamoyl-6- (trifluoromethoxy)-1H-indol-1- yl)pyridin-2-yl)cyclopropane-1- carboxylic acid
28e
cis-(+)-2-(6-(2-carbamoyl-6- (trifluoromethoxy)-1H-indol-1- yl)pyridin-2-yl)cyclopropane-1- carboxylic acid

### Claim 132 (depends on 131)

The compound or pharmaceutically acceptable salt thereof according to claim 131, wherein the compound is selected from:
Compound
Name
Structure
28a
trans-(−)-2-(6-(2-carbamoyl-6- (trifluoromethoxy)-1H-indol-1- yl)pyridin-2-yl)cyclopropane-1- carboxylic acid

### Claim 133

A compound selected from
Compound
Name
Structure
18
3-(6-(2-carbamoy1-6- (trifluoromethoxy)-1H-indol-1- yl)pyridin-2-yl)propanoic acid
22
3-(3-(2-carbamoyl-6- (trifluoromethoxy)-1H-indol-1- yl)phenyl)-3-methylbutanoic acid
30
2-(1-(3-(2-carbamoyl-6- (trifluoromethoxy)-1H-indol-1- yl)phenyl)cyclobutyl)acetic acid
44
2-((6-(2-carbamoy1-6- (trifluoromethoxy)-1H-indol-1- yl)pyridin-2-yl)thio)acetic acid
45
2-((6-(2-carbamoyl-6- (trifluoromethoxy)-1H-indol-1- yl)pyridin-2-yl)sulfonyl)acetic acid
50
(1-(6-(2-carbamoy1-6- (trifluoromethoxy)-1H-indol-1- yl)pyridin-2-yl)cyclobutyl)glycine
59
2-(1-(6-(2-carbamoyl-6- (trifluoromethoxy)-1H-indol-1- yl)pyridin-2-yl)cyclopropyl)acetic acid
62
3-(6-(2-carbamoyl-6- (trifluoromethoxy)-1H-indol-1- yl)pyridin-2-yl)-3-methylbutanoic acid
or a pharmaceutically acceptable salt thereof.

### Claim 134 (depends on 122)

A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof according to claim 122, and a pharmaceutically acceptable carrier.

### Claim 135 (depends on 122)

An in vitro method of inhibiting an sPLA2-X enzyme, said method comprising contacting the enzyme with a compound or pharmaceutically acceptable salt thereof according to claim 122, wherein the compound or pharmaceutically acceptable salt thereof is a selective inhibitor of sPLA2-X over other sPLA2 enzymes.

### Claim 136 (depends on 135)

The in vitro method according to claim 135, wherein the other sPLA2 enzymes are selected from sPLA2-IIE, sPLA2-IIA, and sPLA2-V enzymes.

### Claim 137 (depends on 122)

A method of treating a disease mediated by an sPLA2-X enzyme in a subject, said method comprising administering to the subject a therapeutically effective amount of a composition comprising a compound or pharmaceutically acceptable salt thereof according to claim 122.

### Claim 138 (depends on 137)

The method according to claim 137, wherein the disease is selected from cancer, atherosclerosis, or cardiovascular disease.

### Claim 139 (depends on 138)

The method according to claim 138, wherein the cancer is selected from multiple myeloma (MM), diffuse large B cell lymphoma (DLBCL), B cell lymphoma or non-small cell lung cancer.

### Claim 140 (depends on 139)

The method according to claim 139, wherein the multiple myeloma (MM) and/or diffuse large B cell lymphoma (DLBCL) is recurring, refractory, or relapsing DLBCL and/or MM.

### Claim 141 (depends on 139)

The method according to claim 139, wherein the cancer is selected from B cell lymphoma or non-small cell lung cancer.
